135 related articles for article (PubMed ID: 34307151)
1. The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma.
Shi Y; Wang X; Zhu Q; Chen G
Front Oncol; 2021; 11():685694. PubMed ID: 34307151
[TBL] [Abstract][Full Text] [Related]
2. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
3. Studying the Role and Molecular Mechanisms of
Shi Y; Mo X; Hong S; Li T; Chen B; Chen G
Biomed Res Int; 2020; 2020():4965670. PubMed ID: 33204699
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p.
Ye J; Zhang R; Du X; Chai W; Zhou Q
Onco Targets Ther; 2019; 12():415-422. PubMed ID: 30655679
[TBL] [Abstract][Full Text] [Related]
5. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
6. [Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib].
Ma B; Tian ZH; Qu L; Liu YX; Zhang H; Ding HR
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):207-213. PubMed ID: 32306000
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells.
Wu M; Shen X; Tang Y; Zhou C; Li H; Luo X
PeerJ; 2020; 8():e8624. PubMed ID: 32149026
[TBL] [Abstract][Full Text] [Related]
8. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
10. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells.
Wu MY; Tang YP; Liu JJ; Liang R; Luo XL
J Cancer; 2020; 11(10):2993-3001. PubMed ID: 32226514
[TBL] [Abstract][Full Text] [Related]
11. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
12. HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma.
Shi Y; Yang X; Xue X; Sun D; Cai P; Song Q; Zhang B; Qin L
Onco Targets Ther; 2020; 13():2127-2137. PubMed ID: 32210579
[TBL] [Abstract][Full Text] [Related]
13. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
14. LncRNA model predicts liver cancer drug resistance and validate
Yin Q; Huang X; Yang Q; Lin S; Song Q; Fan W; Li W; Li Z; Gao L
Front Cell Dev Biol; 2023; 11():1174183. PubMed ID: 37077416
[No Abstract] [Full Text] [Related]
15. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
16. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
17. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
18. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Azumi J; Tsubota T; Sakabe T; Shiota G
Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
[TBL] [Abstract][Full Text] [Related]
19. miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression.
Chen X; Tan W; Li W; Li W; Zhu S; Zhong J; Shang C; Chen Y
J Cancer; 2019; 10(12):2745-2753. PubMed ID: 31258782
[No Abstract] [Full Text] [Related]
20. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
Liu J; Qiu WC; Shen XY; Sun GC
Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
